tiprankstipranks
Trending News
More News >
Cts Corp. (CTS)
NYSE:CTS
Advertisement

CTS (CTS) AI Stock Analysis

Compare
124 Followers

Top Page

CTS

CTS

(NYSE:CTS)

Rating:74Outperform
Price Target:
$46.00
▲(8.01% Upside)
CTS's overall stock score reflects its strong financial performance and strategic growth initiatives. The company's robust balance sheet and positive earnings call guidance are significant strengths. However, technical indicators suggest some short-term market challenges, and valuation metrics indicate reasonable pricing. Corporate events further bolster confidence in the company's strategic direction.

CTS (CTS) vs. SPDR S&P 500 ETF (SPY)

CTS Business Overview & Revenue Model

Company DescriptionCTS Corporation manufactures and sells sensors, actuators, and connectivity components in North America, Europe, and Asia. The company provides sensors and actuators for use in passenger or commercial vehicles; connectivity components for telecommunications infrastructure, information technology, and other high-speed applications; switches, temperature sensors, and potentiometers supplied to multiple markets; and fabricated piezoelectric materials and substrates used primarily in medical, industrial, aerospace and defense, and information technology markets. In addition, the company sells and markets its products through its sales engineers, independent manufacturers' representatives, and distributors. CTS Corporation was founded in 1896 and is headquartered in Lisle, Illinois.
How the Company Makes MoneyCTS generates revenue through the sale of its electronic components and sensors to a wide array of industries. The company's key revenue streams include the production of sensors and actuators for aerospace and defense applications, as well as electronic components for industrial and medical devices. Additionally, CTS benefits from long-term relationships with major clients and strategic partnerships that enhance its market presence and drive sales. Their focus on innovation and the development of advanced technologies also contributes to increased demand for their products, further solidifying their revenue model.

CTS Earnings Call Summary

Earnings Call Date:Jul 24, 2025
(Q2-2025)
|
% Change Since: 5.32%|
Next Earnings Date:Oct 22, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with strong growth in diversified end markets, particularly in aerospace and defense, and improved financial metrics. However, challenges in the transportation sector, particularly in China, and softness in certain medical diagnostics segments highlight areas of concern.
Q2-2025 Updates
Positive Updates
Strong Diversified End Market Sales
Diversified end market sales, including medical, aerospace, and defense, were up 13%, driven by organic growth and the SyQwest acquisition. These markets comprised 55% of overall revenue.
Aerospace and Defense Growth
Sales in aerospace and defense increased 34% from the previous year, with a 6% rise excluding the SyQwest acquisition. SyQwest contributed $4.5 million in revenue.
Improved Financial Performance
Adjusted EBITDA improved by 250 basis points sequentially and 130 basis points year-over-year. Adjusted diluted earnings rose to $0.57 per share, a 30% increase from the first quarter and 7% from the prior year.
Strong Cash Flow and Liquidity
Operating cash flow was $28 million in the second quarter, with a cash balance of $99 million and long-term debt at $88 million, providing good liquidity for strategic acquisitions.
Industrial Market Recovery
Industrial market sales were up 5% sequentially and 6% year-over-year, with bookings increasing 22% from the same period last year.
Negative Updates
Decline in Transportation Sales
Transportation sales were $61 million, down approximately 6% year-over-year due to China market dynamics and softness in commercial vehicle products.
Softness in Diagnostic Ultrasound
Bookings in the medical end market were down 10% year-over-year due to softness in diagnostic ultrasound bookings.
Challenges in China
The China market faced dynamics impacting transportation sales, and there's potential softness in commercial vehicle-related revenue anticipated for the remainder of the year.
Company Guidance
During the second quarter of 2025, CTS Corporation provided guidance indicating a solid financial performance and strategic progress amidst challenging market conditions. The company reported sales of $135 million, marking a 4% increase year-over-year, with diversified end market sales rising by 13%, significantly driven by the SyQwest acquisition which contributed $4.5 million. Adjusted EBITDA improved by 250 basis points sequentially and 130 basis points from the previous year. Diversified markets accounted for 55% of overall revenue, with aerospace and defense sales soaring by 34%, including a 6% organic growth. The medical market saw an 8% sales increase with therapeutic products up 60%. However, transportation sales fell by 6% due to China market dynamics. The company maintained its full-year guidance, projecting sales between $520 million and $550 million, and adjusted diluted EPS ranging from $2.20 to $2.35. CTS emphasized its strategic focus on diversification, operational efficiency, and strategic acquisitions to support long-term growth, despite external pressures from tariffs and geopolitical uncertainties.

CTS Financial Statement Overview

Summary
CTS demonstrates a robust financial position with solid profitability and cash flow metrics. While revenue growth has faced challenges, the company maintains strong operational margins and a healthy balance sheet.
Income Statement
75
Positive
The income statement of CTS depicts a stable gross profit margin and improving net income over the TTM period. However, there is a noticeable decline in total revenue compared to previous years, indicating potential challenges in revenue growth. Despite this, the company maintains decent EBIT and EBITDA margins, showcasing operational efficiency.
Balance Sheet
80
Positive
CTS exhibits a strong balance sheet with a high equity ratio and manageable debt levels, reflected in a moderate debt-to-equity ratio. The company has a solid return on equity, indicating effective utilization of shareholder funds. However, fluctuations in total assets and equity warrant close monitoring.
Cash Flow
78
Positive
The cash flow statement indicates a healthy operating cash flow with a consistent free cash flow generation over the years. The free cash flow to net income ratio is strong, suggesting efficient cash conversion from earnings. However, investing and financing cash flows show volatility, which could impact future liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue515.77M550.42M586.87M512.92M424.07M
Gross Profit189.15M190.86M210.54M184.62M139.06M
EBITDA108.17M107.19M113.22M-32.58M74.99M
Net Income58.11M60.53M59.58M-41.87M34.69M
Balance Sheet
Total Assets766.11M741.17M748.49M664.46M626.05M
Cash, Cash Equivalents and Short-Term Investments94.33M163.88M156.91M141.47M91.77M
Total Debt117.09M96.86M109.36M74.75M81.06M
Total Liabilities235.26M214.34M242.26M200.88M202.37M
Stockholders Equity530.85M526.82M506.22M463.58M423.68M
Cash Flow
Free Cash Flow80.64M74.07M106.86M70.50M61.92M
Operating Cash Flow99.29M88.81M121.20M86.14M76.78M
Investing Cash Flow-140.56M-18.10M-111.19M-15.90M-23.17M
Financing Cash Flow-27.93M-65.40M4.34M-20.71M-61.33M

CTS Technical Analysis

Technical Analysis Sentiment
Positive
Last Price42.59
Price Trends
50DMA
41.60
Positive
100DMA
40.79
Positive
200DMA
45.56
Negative
Market Momentum
MACD
-0.35
Negative
RSI
61.12
Neutral
STOCH
79.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTS, the sentiment is Positive. The current price of 42.59 is above the 20-day moving average (MA) of 40.34, above the 50-day MA of 41.60, and below the 200-day MA of 45.56, indicating a neutral trend. The MACD of -0.35 indicates Negative momentum. The RSI at 61.12 is Neutral, neither overbought nor oversold. The STOCH value of 79.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTS.

CTS Risk Analysis

CTS disclosed 38 risk factors in its most recent earnings report. CTS reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CTS Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$4.82B52.335.89%14.24%424.78%
77
Outperform
$2.18B34.0911.44%2.46%572.04%
74
Outperform
$1.22B19.5511.96%0.38%1.16%19.81%
69
Neutral
$1.42B37.843.49%1.71%-5.95%-43.46%
68
Neutral
¥241.22B15.246.62%2.44%9.24%1.58%
57
Neutral
$1.36B72.21-5.25%-7.61%-212.91%
42
Neutral
$348.08M-0.38%0.92%8.33%99.75%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTS
CTS
42.59
-4.48
-9.52%
BHE
Benchmark Electronics
40.56
-1.41
-3.36%
MLAB
Mesa Laboratories
69.28
-58.96
-45.98%
ROG
Rogers
77.95
-29.10
-27.18%
TTMI
TTM Technologies
44.96
26.22
139.91%
VICR
Vicor
49.48
10.56
27.13%

CTS Corporate Events

Business Operations and Strategy
CTS Corporation Highlights Growth Strategy in Investor Presentation
Positive
Jul 24, 2025

CTS Corporation presented an investor presentation for the fiscal year ending December 31, 2025, highlighting its strategic focus on growth and diversification across various end markets. The company aims to deliver 10% organic and inorganic growth by leveraging its deep custom engineered capabilities, strong customer relationships, and a robust new product pipeline. CTS is positioned to capitalize on megatrends such as automation, healthcare innovation, and electrification, supported by a strong balance sheet and cash flow to pursue strategic mergers and acquisitions. The company’s diversified end markets, including industrial, medical, and aerospace and defense, show promising growth prospects with significant revenue contributions and market opportunities.

The most recent analyst rating on (CTS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
CTS Reports Q2 2025 Financial Results with Growth
Positive
Jul 24, 2025

On July 24, 2025, CTS Corporation announced its financial results for the second quarter of 2025, reporting a 4% year-over-year increase in sales to $135 million. The company achieved a net income of $19 million, up from $15 million in the same quarter of 2024, and an adjusted EBITDA margin of 23.0%. Despite a 6% decrease in sales to the transportation market, sales to diversified end markets grew by 13%. CTS maintains its 2025 guidance for sales and adjusted diluted EPS, indicating a focus on strategic diversification through organic growth and acquisitions.

The most recent analyst rating on (CTS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
CTS Appoints Mark Pacioni as Chief Legal Officer
Positive
Jul 2, 2025

On July 1, 2025, CTS Corporation appointed Mark Pacioni as Chief Legal & Administrative Officer and Corporate Secretary. Mr. Pacioni brings over 30 years of legal experience, having previously served in senior roles at CareerBuilder, LLC, and its successor, as well as at Knowles Corp., Molex, Inc., and Boeing. His extensive background is expected to contribute significantly to CTS’s global strategy and business diversification efforts.

The most recent analyst rating on (CTS) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 13, 2025